SCHEMBL23313008

SCHEMBL23313008

COc1ccc(CNc2ncnc3c2c(-c2ccn(C)n2)cn3[C@@H]2C[C@H](CO)[C@@H](O)C2)c(OC)c1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ METTL3 Q86U44 5/20 0.48
▸ PRMT5 O14744 3/20 0.40
▸ WDR77 Q9BQA1 2/20 0.40
▸ ABL1 P00519 1/20 0.39
▸ EGFR P00533 1/20 0.39
▸ ABL2 P42684 1/20 0.39
▸ CYP1A2 P05177 11/20 0.39
▸ CYP3A4 P08684 11/20 0.39
▸ CYP2C19 P33261 11/20 0.39
▸ TSHR P16473 8/20 0.39
▸ ALDH1A1 P00352 6/20 0.39
▸ HSD17B10 Q99714 6/20 0.39
▸ CYP2C9 P11712 5/20 0.39
▸ CLK4 Q9HAZ1 5/20 0.39
▸ LMNA P02545 3/20 0.39
▸ CYP2D6 P10635 9/20 0.39
▸ MAPK1 P28482 3/20 0.39
▸ ALOX15 P16050 3/20 0.38
▸ USP2 O75604 2/20 0.38
▸ CASP1 P29466 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29772295 1.00 METTL3 (0.48) METTL3PRMT5WDR77ABL1EGFR
SCHEMBL29772294 1.00 METTL3 (0.48) METTL3PRMT5WDR77ABL1EGFR
SCHEMBL29772274 0.89 METTL3 (0.47) METTL3PRMT5WDR77CYP1A2CYP3A4
SCHEMBL25015554 0.89 METTL3 (0.47) METTL3PRMT5WDR77CYP1A2CYP3A4
SCHEMBL29772286 0.88 METTL3 (0.39) METTL3PRMT5WDR77ABL1EGFR
SCHEMBL25016861 0.88 METTL3 (0.39) METTL3PRMT5WDR77ABL1EGFR
SCHEMBL30060440 0.87 METTL3 (0.42) METTL3PRMT5WDR77ABL1EGFR
SCHEMBL23274005 0.87 METTL3 (0.46) METTL3PRMT5WDR77CYP1A2CYP3A4
SCHEMBL30057121 0.87 METTL3 (0.46) METTL3PRMT5WDR77CYP1A2CYP3A4
SCHEMBL25015921 0.85 METTL3 (0.72) METTL3PRMT5WDR77

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230027361-A1 METTL3 MODULATORS ACCENT THERAPEUTICS, INC. (US) 2023-01-26 — — US disclosed
US-20230027361-A1 METTL3 MODULATORS ACCENT THERAPEUTICS, INC. (US) 2023-01-26 — — US disclosed
WO-2021079196-A9 METTL3 MODULATORS ACCENT THERAPEUTICS, INC (US) 2022-07-14 — — WO disclosed
WO-2021079196-A2 METTL3 MODULATORS ACCENT THERAPEUTICS, INC (US) 2021-04-29 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230027361-A1 METTL3 MODULATORS METTL3, METTL16, METTL14 METTL3 1/4885PRMT5 69/4885WDR77 98/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback